© Cambridge University Press 2018. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. doi:10.1017/50266462318000594

IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE

Marlene Gyldmark

MORSE – Health Technology Assessment Group, F. Hoffmann-La Roche, Pharmaceuticals Division, Global Pricing and Market Access marlene.gyldmark@roche.com

Kristian Lampe Independent HTA expert

Jörg Ruof r-connect GmbH Johannes Pöhlmann Ossian Health Economics and Communications

Ansgar Hebborn Global Market Access Policy, F. Hoffmann-La Roche

Finn Børlum Kristensen Faculty of Health Sciences, University of Southern Denmark

Objectives: The HTA Core Model[®] was developed to improve the transferability of health technology assessment (HTA) between settings. The model has been used by HTA agencies but is also of interest to manufacturers, for improving internal evidence generation and communicating with other HTA stakeholders. To establish if the model is fit for purpose from an industry perspective, the pharmaceutical company Roche, collaborating with the European Network for HTA (EUnetHTA), conducted an assessment of the model. **Methods:** A questionnaire was developed to evaluate all assessment elements in the HTA Core Model v2.0 for their usefulness in meeting payers' evidence needs and demonstrating

value. The questionnaire was completed by country affiliate teams working in evidence generation and reimbursement submissions for pharmaceuticals. Survey results were discussed in workshops to ensure consistency and alignment between teams.

Results: The questionnaire was completed by six teams. An additional team from global pricing and market access participated in workshops. Model domains pertaining to the health problem and current technology use, technology description, clinical effectiveness, and economic value were considered most important because they meet payers' evidence needs. Overall, the model was considered useful to improve the efficiency of HTA evidence generation, share evidence internally, and communicate value to payers and HTA agencies. **Conclusions:** From an industry perspective, the HTA Core Model provides a useful framework and common terminology for efficient generation of transferable HTA evidence. The timeliness, efficiency, and transparency of HTA processes could be improved by a more standardized approach to HTA across settings.

Keywords: Technology assessment, Biomedical, Economics, Pharmaceutical, Biomedical technology, Healthcare sector, Reference standards

Healthcare systems struggle to provide access to innovative health care with limited budgets so prefer to allocate funding to technologies with demonstrated value for money (1;2). Establishing the value of a new technology, however, is a complex process. Multiple perspectives on value must be considered and reconciled as stakeholders, including payers, patients, and manufacturers, put forward an increasing number of different value definitions (2).

Health technology assessment (HTA) is designed to inform value judgements and policy making (1;3). HTA systematically and transparently summarizes the evidence on various properties of a healthcare technology and the likely consequences of its adoption (3;4). Certain aspects of HTA are context-specific as comparators, disease burden, patient preferences, resource use, and costs often vary between settings (3;5).

Some elements, however, can be transferred (6). Transferring elements has the potential to reduce duplicated work and increase the efficiency of evidence development, thereby saving resources while improving the transparency and predictability of the HTA process (3;7). The HTA Core Model[®] ("the model") was

designed by the European Network for HTA (EUnetHTA) to address this issue of transferability (6–8). The model provides a standardized framework to generate and share HTA evidence while enabling collaboration and avoiding duplication of work. However, the model is designed to be flexible so model users can select assessment elements that best fit their needs and integrate the selected elements into their specific reporting formats.

Evaluations of the model have been conducted from the perspective of HTA agencies but an industry perspective is currently lacking (9). In 2013, F. Hoffmann-La Roche (Roche) and EUnetHTA agreed on a project to investigate how the model can support HTA evidence generation within Roche. Roche wanted to explore whether the model can guide the development of HTA evidence, be a repository for sharing evidence internally and serve as a framework for discussing the value of innovative medicines with payers, HTA agencies and other HTA stakeholders. Using the model has the potential for Roche (and other HTA evidence contributors) to become more efficient in developing HTA evidence and preparing pricing and reimbursement activities at the global and local level.
 Table 1. Domains in the HTA Core Model Application for Pharmaceuticals (v2.0)

Domain (abbreviation; order in model)	Topics in the domain	No. of assessment elements
Health problem and current use of technology (CUR; 1)	Target population and condition; current management; utilization of technology; regulatory status ^a	20
Description and technical characteristics of technology (TEC; 2)	Features of the technology; investments and tools required for technology use; training and information required for technology use; other	15
Safety (SAF; 3)	Patient, occupational and environmental safety; safety risk management	13
Clinical effectiveness (EFF; 4)	Function; mortality; morbidity; benefit-harm balance; health-related quality of life; change in management of condition; patient satisfaction	15
Costs and economic evaluation (ECO; 5)	Resource utilization; outcome measurement/estimation; examination of costs and outcomes; characterizing uncertainty and heterogeneity; model validity	8
Ethical analysis (ETH; 6)	Beneficence/nonmaleficence; autonomy; respect for persons; justice and equity; legislation; ethical consequences of health technology assessment	19
Organizational aspects (ORG; 7)	Health delivery process; structure of health care; process-related costs; management; culture	14
Social aspects (SOC; 8) ^b	Individual (e.g., changes affecting patient or caregivers); major life areas (e.g., influence on inequality in health); information exchange	11
Legal aspects (LEG; 9) ^c	Patient autonomy and privacy; equality in health care; authorization and safety; ownership and liability; market regulation	15

Note. Table references: Model Handbook 1.1 and deliverables for model versions 2.0, 2.1, 3.0 (10-13).

^aMoved to TEC domain in version 3.0.

^b"Patients and social aspects" in v3.0, includes topics "Patients' perspectives," "Social group aspects," and "Communication aspects." ^cSourced from (draft) version 2.1.

METHODS

The HTA Core Model was originally developed during the EUnetHTA Project (2006-08), following detailed review of the HTA process, and was expanded and improved further in EUnetHTA Joint Actions 1 (2010-12) and 2 (2012-15) (6-8). Model applications are available for the assessment of medical/surgical interventions, diagnostic or screening technologies, and pharmaceuticals (10-13). The model has three components: the ontology, methodological guidance on conducting the assessment, and a common reporting structure to standardize outputs. The ontology is designed to guide evidence collection and assessment, by structuring information in nine domains (Table 1). Domains are divided into topics, each of which in turn contains issues of relevance to HTA. Issues are phrased as generic questions and, combined with their respective domain and topic, form an assessment element (10;11).

A survey was conducted at Roche in June 2014 to evaluate if the nine-domain model application for pharmaceuticals (version 2.0) was fit for purpose, that is, represented a useful framework for standardized evidence generation and value assessment, from an industry perspective. Usefulness was defined according to the following criteria: (i) Importance to payers: Assessment elements were classified as useful if they met payers' needs, for example, for benefit assessment in pricing and reimbursement negotiations or formulary listing. The term "payer" was used broadly, to denote national or local payers, reimbursement decision makers or providers of guidance. (ii) Relevance for value proposition: Elements were classified as useful if they contributed, during the initial submission or in the future, to demonstrating and communicating the value of the technology

An online questionnaire was developed to appraise the importance and transferability of all 130 assessments elements (Table 2). The model was also evaluated for possible redundancy of elements and for elements missing from the model.

The questionnaire was drafted following an initial workshop of the Global Pricing and Market Access (GPMA) team. The draft was piloted with the United Kingdom country affiliate, and the questionnaire revised in line with affiliate feedback. The final questionnaire was shared with country affiliate teams who completed one online questionnaire per team. All country affiliate staff participating in the survey were directly involved in evidence development, reimbursement submissions or payer negotiations for pharmaceuticals, to reflect experiences and needs associated with production and use of HTA within Roche.

Data from completed questionnaires were analyzed using descriptive statistics and collated results were returned to country affiliates for preparation of workshops. In one workshop per country and a joint workshop attended by delegates Gyldmark et al.

Table 2. HTA Core Model Evaluation Questionnaire

Question	Instructions
Is the assessment element important because payers ask for it?	Assess importance for benefit assessment, price, reimbursement negotiation, formulary listing as "very important," "somewhat important," "somewhat unimportant," or "very unimportant" Select the payer level (national; regional and local; national, regional, and local) where this element is important (if applicable)
Is the assessment element relevant to demonstrate the value proposition?	Select the payer level (national; regional and local; national, regional, and local) where this element is important
Are there any other reasons why it is important?	Provide reasons for importance not covered above
Is the assessment element of low importance?	Provide reasons for low importance
Which type of information is transferable between different health care systems?	Assess transferability as "fully," "partially," or "not transferable"
Does the assessment element duplicate information?	Specify which assessment element is duplicated
Are any assessment elements missing?	Specify which assessment element is missing from a Roche perspective
Are any assessment elements unclear?	—
Is any assessment element redundant?	_

from country affiliates and the GPMA team in September 2014, open questions and between-country differences were discussed to establish a common understanding of assessment elements. Following the workshops, country affiliates had the opportunity to revise their initial answers before the summary report was drafted based on questionnaire results and discussions at workshops. After review by country affiliates and EUnetHTA, the final report, which included the survey questions and detailed results, was published on the EUnetHTA Web site in December 2014 (14).

RESULTS

Teams from six country affiliates (Canada, France, Germany, Italy, the Netherlands, United Kingdom) with a total of thirtyone staff participated in the survey and local workshops (Table 3). An additional four GPMA staff participated in the joint workshop.

On average, 67 percent of all assessment elements were considered important by country affiliates (Figure 1). Differences in the average percentage of important elements were observed across domains. In four of the first five domains (health problem/current use of technology, characteristics of technology, clinical effectiveness, costs, and economic evaluation), \geq 70 percent of elements were judged to be important while the fifth domain (safety) was less important. In other domains, between 40 percent (legal aspects) and 62 percent (organizational aspects) of elements were considered important. Of note, as the legal domain was developed referencing European law, elements of this domain were not immediately applicable to the Canadian setting and were, therefore, considered to be of low importance by the Canadian team.

Just over half (51 percent) of elements were considered to be transferable between settings (Figure 1). The safety and clinical effectiveness domains had the highest shares of transferable elements, with 90 percent and 79 percent, respectively. In the economic, ethical, organization, social, and legal domains, <50 percent of elements were deemed transferable.

Workshop discussions expanded on survey results. Overall, the first five domains were considered crucial for reimbursement as they reflected payers' current evidence needs and demonstrated the value of a technology. Safety, however, was of lower importance in the context of the model as safety is already covered by regulatory requirements so, for some safety elements, payers may require less evidence to be discussed in HTA than for elements in other domains.

In addition, there is often a paucity of data for some safetyrelated assessment elements, for example, elements covering public and environmental risk. The last four domains were judged to be less important because few payers currently require their inclusion. Workshop participants agreed that these domains could be used to demonstrate the value of a technology from the perspectives of different stakeholders. However, elements in these domains often require context-specific evidence and were, therefore, considered to have low between-context transferability. Some participants also considered these four domains to be less important due to shortcomings in how domains were implemented in the model, for example, because some elements in these domains were unclear or because some elements were considered to be missing.

In discussions on the usefulness of the model for manufacturers, several potential benefits were identified. The model was considered, from the industry perspective of Roche, to provide an exhaustive, standardized framework for scoping




Fig. 1. Results of the online survey, averaged across all six country affiliates.

Table 3. Characteristics of Teams Participating in the Survey

Team	Perspective on payers/HTA agencies	Team size
Canada	Payers from national and provincial levels	4
France	Payers from national and local levels	10
Germany	Payers (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen), Gemeinsamer Bundesausschuss	6
Italy	Payers from national, regional and local levels	4
Netherlands	Payers	5
United Kingdom	Cancer Drugs Fund; National Institute for Health and Care Excellence; Scottish Medicines Consortium	2
Global	Payers, across multiple EU countries	4

and generating HTA evidence. Participants agreed that such a standardized approach would improve the comparability and quality of HTA processes, by providing a shared HTA terminology for communication internally (e.g., across affiliates) and externally (e.g., with payers in different settings).

Participants also explained that the model would enable a comprehensive, checklist-style approach to generate evidence more consistently within the company. It was suggested that the model could be used as a company-wide repository for HTA submissions to reduce duplicated work by sharing transferable elements. Following this internal survey, an access evidence generation process was implemented at Roche, which relies on tools developed on the basis of the model and its assessment to provide a standardized, systematic, and consistent approach to plan and generate evidence for HTA submissions.

Limitations of the model that might reduce its usefulness were also discussed. Participants agreed that, from an industry perspective, model usability could be improved with a more targeted version of the model, for example, by excluding duplicated elements and elements considered less important in the survey. Participants expressed concerns that it was not clear if and when future versions of the model would be developed. It was also unclear if model usage should be expected to extend beyond its current use cases, for example, to use in reimbursement decision making, and would be accepted by national and sub-national decision makers.

DISCUSSION

The present study provides evidence that the HTA Core Model is fit for purpose from an industry perspective and a useful tool for evidence generation and value propositions for healthcare technologies. Despite the need for some modifications, for example removal of duplicated and unimportant elements as identified in the survey, the model was considered as a valuable tool for sharing evidence across settings and discussing value, both internally and with other HTA stakeholders such as payers and HTA agencies.

This assessment, albeit from a different stakeholder perspective, was aligned with recent evaluations conducted by HTA agencies and the European Commission (9;15;16). In a comparison of the model with national HTA reports in the Netherlands and Luxembourg, 40 percent and 50 percent of model elements, respectively, were judged relevant for the national assessment (15;17). Of relevant elements, 64 percent and 47 percent, in the Netherlands and Luxembourg, respectively, were already included in national report templates. In both studies, including interviews with representatives from European HTA agencies and surveys of national uptake of the model, some elements were considered to be redundant or of limited value. There also was some concern that decision makers might be uncomfortable with new HTA formats and question the use of the model. On balance, the model was deemed to offer an opportunity for standardized, comprehensive, and collaborative HTA and evidence generation (15;17).

While the survey reported here produced results similar to those obtained by HTA agencies, the survey is not without limitations. A relatively small sample of staff assessed the model and results may not be readily generalizable to other manufacturers, for example, companies of a different size and structure or those working in different markets or therapeutic areas. It should be noted, though, that participants were experienced in evidence generation and reimbursement submissions in a wide range of contexts. Their perspective was considered to be comprehensive and likely applicable to other HTA evidence contributors. The lack of formal validation of the questionnaire may be considered another limitation. The questionnaire, however, was designed to follow closely earlier evaluations conducted by EUnetHTA and was piloted with a country affiliate team. In addition, participants' understanding of the questionnaire was aligned and confirmed in workshops.

Since this study was performed, version 3.0 of the model has become available. Results of the survey were taken into account by the model developers, along with feedback from other sources, when designing version 3.0: Some elements considered by Roche staff to be unimportant or duplicated in version 2.0 were removed or included in other elements in version 3.0. These changes reflect the responsiveness of model developers to input from stakeholders. Together with patients, providers, and payers, manufacturers have been a key stakeholder in EUnetHTA since the EUnetHTA Project and have provided input to all model versions. From the perspective of manufacturers, inconsistent HTA requirements between settings are associated with high costs as evidence generation has to be duplicated or available evidence must be extensively adapted (5;18). A standardized framework such as the HTA Core Model, which enables sharing and reuse of evidence internally and with HTA bodies in different settings, would be useful to reduce the cost and improve the timeliness of HTA for both manufacturers and HTA bodies (5).

Different HTA requirements not only increase the cost of evidence generation, they also suggest that the same evidence may be interpreted differently and lead to different HTA outcomes (5;18;19). The lack of consistency and transparency in evidence interpretation and appraisal between settings makes HTA processes less predictable for patients, clinicians, and manufacturers. Again, standardizing requirements across contexts, coupled with transparent, consistent decision frameworks, improves manufacturers' ability to plan and predict assessment and reimbursement of their products. In turn, these improvements are likely to spur research and innovation and reduce the time and cost of making healthcare technologies available to patients.

From the perspective of all HTA stakeholders, standardizing the HTA process, particularly with regard to the scope and methodology of evidence generation, also helps to make HTA better equipped for the increasing demands on HTA, such as assessing technologies earlier and over longer periods, for example, over the technology's lifecycle (20). At the same time, the number of stakeholders and value definitions to be considered is likely to increase (2;20). These developments will require additional resources and might lead to even larger variability in HTA processes. An agreed-upon, standardized structure and terminology for HTA, which enables collaboration and can accommodate various value definitions, is likely to help all HTA stakeholders to meet increased demands on their resources and time without comprising the quality of the HTA process.

While attempts to standardize HTA are in relatively early stages, standardization is recognized to be associated with efficiency and quality benefits in medical research and regulatory approval (21;22). Similar to the HTA Core Model, these efforts are designed to improve the transparency and quality of research (21). Producers and users of evidence benefit from reliable frameworks which increase the comparability and reproducibility of results.

These benefits of standardization are similar to those obtained in other industries (23;24). Standardization is associated with more effective, less costly information exchange. In addition, standards contribute to economic and productivity growth and innovation through faster dissemination of new knowledge and increased confidence of producers and consumers (23;24). It seems plausible that similar benefits can be derived from a standardized approach to HTA.

In conclusion, in an online survey and workshops conducted at Roche, staff with experience in pricing and reimbursement submissions for pharmaceuticals at the global and local level assessed the usefulness of the HTA Core Model. From the industry perspective of Roche, the HTA Core Model was found to be fit for purpose as a framework for standardized evidence generation, as a repository for efficient sharing of evidence between settings and as a common terminology for value discussions with other HTA stakeholders, including payers and HTA agencies. Domains covering burden of disease and current technology use, features, clinical effectiveness, and economic evaluation of the technology were most relevant to demonstrate the value of healthcare technologies, particularly of pharmaceuticals. The results of this analysis were used as a primer for future research on using the HTA Core Model for access evidence generation within Roche.

CONFLICTS OF INTEREST

Marlene Gyldmark and Ansgar Hebborn are employees of F. Hoffmann-La Roche. Jörg Ruof was an employee of F. Hoffmann-La Roche when the work described in this paper was performed. Johannes Pöhlmann is an employee of Ossian Health Economics and Communications, which received consulting fees from F. Hoffmann-La Roche to support the preparation of this article. Kristian Lampe was an employee of the Finnish National Institute for Health and Welfare, working for EUnetHTA Joint Action 2 (Work package 8) when this work was performed and later received consultancy fees from F. Hoffmann-La Roche. Finn Børlum Kristensen received consultancy fees from F. Hoffmann-La Roche. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Kristian Lampe and Finn Børlum Kristensen contributed to the development and dissemination of the original and subsequent versions of the HTA Core Model[®].

REFERENCES

- Henshall C, Schuller T. Health technology assessment, value-based decision making, and innovation. *Int J Technol Assess Health Care*. 2013;29: 353–359.
- Lakdawalla DN, Doshi JA, Garrison LP, Jr, et al. Defining elements of value in health care: A health economics approach: An ISPOR Special Task Force Report [3]. *Value Health*. 2018;21:131–139.
- Akehurst RL, Abadie E, Renaudin N, Sarkozy F. Variation in health technology assessment and reimbursement processes in Europe. *Value Health*. 2017;20:67–76.
- 4. European Network for Health Technology Assessment (EUnetHTA). Common questions: What is health technology assessment (HTA)? No date. eunethta.eu/services/submission-guidelines/submissions-faq/ (accessed July 19, 2018).
- 5. Lothgren M, Ratcliffe M. Pharmaceutical industry's perspective on health technology assessment. *Int J Technol Assess Health Care*. 2004;20:97–101.
- 6. Kristensen FB, Lampe K, Wild C, et al. The HTA Core Model[®]: 10 years of developing an international framework to share multidimensional value assessment. *Value Health*. 2017;20:244–250.
- Lampe K, Mäkelä M, Garrido MV, et al. The HTA Core Model: A novel method for producing and reporting health technology assessments. *Int J Technol Assess Health Care*. 2009;25(Suppl 2):9–20.
- 8. Kristensen FB, Mäkelä M, Neikter SA, et al. European network for Health Technology Assessment, EUnetHTA: Planning, development, and implementation of a sustainable European network for health

technology assessment. Int J Technol Assess Health Care. 2009;25 (Suppl 2):107–116.

- Macpherson K, Thompson L. Experiences in adapting European Network for Health Technology Assessment Rapid Reviews to inform local decision making. *Int J Technol Assess Health Care*. 2017;33: 155–159.
- European Network for Health Technology Assessment (EUnetHTA) Joint Action 2, Work Package 8. HTA Core Model User guide: Version 1.1.2016. htacoremodel.info/documents/HTACoreModel_UserGuide_ Version1.1.pdf (accessed July 19, 2018).
- European Network for Health Technology Assessment (EUnetHTA) Joint Action 2, Work Package 8. HTA Core Model Version 3.0 for the full assessment of diagnostic technologies, medical and surgical interventions, pharmaceuticals and screening technologies. 2016. htacoremodel. info/model/HTACoreModel3.0.pdf (accessed July 19, 2018).
- European Network for Health Technology Assessment (EUnetHTA) Joint Action 2, Work Package 8. HTA Core Model® version 2.1.2015. htacoremodel.info/model/HTACoreModel2.1.pdf (accessed July 19, 2018).
- European Network for Health Technology Assessment (EUnetHTA) Joint Action 2, Work Package 8. HTA Core Model® version 2.0. htacoremodel.info/model/HTACoreModel2.0.pdf (accessed July 19, 2018).
- 14. F. Hoffmann-La Roche. Roche Pharma report relating to EUnetHTA HTA Core Model[®] applications for pharmaceuticals. 2014. eunethta.eu/ wp-content/uploads/2018/01/roche_pharma_report_on_the_hta_core_ model_december2014_0.pdf (accessed July 19, 2018).
- Pasternack I, de Groot I, Kleijnen S, Polman P. Comparing the HTA Core Model with a national health technology assessment report. *Int J Technol Assess Health Care*. 2014;30:530–535.
- European Commission Directorate-General for Health and Food Safety. Mapping of HTA methodologies in EU and Norway. 2017. ec.europa. eu/health/sites/health/files/technology_assessment/docs/2018_mapping_ methodologies_en.pdf (accessed July 19, 2018).
- Kõrge K, Berndt N, Hohmann J, Romano F, Hiligsmann M. Evaluation of the HTA Core Model for national health technology assessment reports: Comparative study and experiences from European countries. *Int J Technol Assess Health Care*. 2017;33:644–653.
- European Federation of Pharmaceutical Industries and Associations (EFPIA). Assessing the wider benefits of the EU's proposal on strengthening cooperation on health technology assessment from the industry perspective: Final report. 2017. efpia.eu/media/219813/cra-efpia-european-cooperation-on-hta-impact-assessment-final-report-july-2017-stc.pdf (accessed July 19, 2018).
- Fischer KE, Heisser T, Stargardt T. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. *Health Policy*. 2016;120:1115–1122.
- Husereau D, Henshall C, Sampietro-Colom L, Thomas S. Changing health technology assessment paradigms? *Int J Technol Assess Health Care*. 2016;32:191–199.
- Simera I, Moher D, Hirst A, et al. Transparent and accurate reporting increases reliability, utility, and impact of your research: Reporting guidelines and the EQUATOR Network. *BMC Med.* 2010;8:24.
- International Council for Harmonisation (ICH). M4: The Common Technical Document. No date. ich.org/products/ctd.html (accessed July 19, 2018).
- International Organization for Standardization. Economic benefits of standards. 2014. iso.org/files/live/sites/isoorg/files/archive/pdf/en/ebs_ case_studies_factsheets.pdf (accessed July 19, 2018).
- 24. Centre for Economics and Business Research (Cebr). The economic contribution of standards to the UK Economy. 2015. bsigroup.com/Local Files/en-GB/standards/BSI-The-Economic-Contribution-of-Standards-tothe-UK-Economy-UK-EN.pdf (accessed July 19, 2018).